drotaverin and Pain

drotaverin has been researched along with Pain* in 3 studies

Trials

2 trial(s) available for drotaverin and Pain

ArticleYear
Interactions between symptoms and motor and visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics).
    Journal of gastrointestinal and liver diseases : JGLD, 2009, Volume: 18, Issue:1

    to evaluate and correlate the symptomatic, motor and sensory responses to two widely used categories of spasmolytic agents in irritable bowel syndrome (IBS).. 118 patients with IBS, diagnosed by Rome II criteria and 45 healthy individuals were studied. In the IBS subjects, pain severity, as well as the sensory response to rectal balloon distention and rectal and sigmoid motility, were studied at baseline and after two weeks therapy with either oral buscopan (20 mg three times a day, n=37), a buscopan suppository (30 mg once daily, n=21), oral drotaverine (80 mg three times a day, n=30), calcium gluconate tablets (one three times a day, n=16) as a control for oral agents, or calendula suppository (once daily, n=14) as a control for those who received a suppository.. Buscopan, whether administered as a tablet or a suppository, produced a significant reduction in pain scores among IBS patients with predominant diarrhea. No significant differences were evident among other IBS subgroups or in response to drotaverine. None of the interventions had any effect on any of the parameters of rectal or sigmoid motility studied. However, both buscopan and drotaverine led to a significant augmentation of the rectal threshold for discomfort/pain among IBS subjects with predominant diarrhea [21.78 + or - 2.8 vs 39.60 + or - 2.4 (p<0.05), 20.5 + or - 2,8 vs 36.84 + or - 3.8 (p<0.05) and 22.18 + or - 2.8 vs 36.9 + or - 2.42 (p<0.05) for oral buscopan, rectal buscopan and oral drotaverine, respectively].. We conclude that the clinical benefits of supposed spasmolytic (anti-spasmodic) agents may relate more to effects on visceral sensation than motility.

    Topics: Administration, Oral; Administration, Rectal; Adult; Butylscopolammonium Bromide; Calcium Gluconate; Calendula; Colon, Sigmoid; Diarrhea; Female; Gastrointestinal Motility; Humans; Irritable Bowel Syndrome; Male; Motor Neurons; Pain; Pain Measurement; Papaverine; Parasympatholytics; Plant Preparations; Rectum; Sensory Receptor Cells; Severity of Illness Index; Suppositories; Tablets; Treatment Outcome; Young Adult

2009
[Using prostaglandin inhibitor dicloberl in patients with ureteral calculi].
    Likars'ka sprava, 2004, Issue:2

    75 patients have been given prostaglandin inhibitor dicloberl in a complex therapy. Comparative analysis of traditionally treated patients with renal stones and with dicloberl in a complex therapy is presented in the article. The combination of dicloberl with tramadol was found to be more effective drug treatment for patients with renal colic. This treatment has to be applied for patients with renal stones up to 6 mm. It is an effective pharmacotherapy for excreting renal stones.

    Topics: Adult; Aged; Analgesics, Opioid; Diclofenac; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pain; Papaverine; Parasympatholytics; Prostaglandin Antagonists; Tramadol; Treatment Outcome; Ureteral Calculi

2004

Other Studies

1 other study(ies) available for drotaverin and Pain

ArticleYear
Examination of the pain relieving-effect of intra-arterial No-Spa treatment of coxarthrosis.
    Therapia Hungarica (English edition), 1982, Volume: 30, Issue:2

    Topics: Adult; Aged; Female; Hip Joint; Humans; Injections, Intra-Arterial; Male; Middle Aged; Osteoarthritis; Pain; Papaverine; Parasympatholytics

1982